Scope, Claim Analysis, and US Patent Landscape for US Patent 12,447,128
US 12,447,128 is a US method-of-treatment patent that claims oral prostate-cancer treatment using a specific fixed-dose tablet composition built around a spray-dried dispersion of enzalutamide with a defined polymer system and performance targets. The core claim engine is formulation-and-performance, not therapeutic regimen novelty: the claims define (i) the tablet count (two tablets per 160 mg enzalutamide dose), (ii) the internal tablet composition (80 mg amorphous enzalutamide plus 400 mg hydroxypropyl methylcellulose acetate succinate per tablet, with inactive excipients), and (iii) in dependent claim variations, specific bioavailability equivalence and solid-state stability metrics.
What is the claimed invention in plain technical terms?
1) Drug substance form and key excipient
All four claims share the same formulation construct inside each of the two tablets:
- Drug: enzalutamide
- Solid-state form: 80 mg amorphous enzalutamide per tablet
- Polymer carrier: 400 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS) per tablet
- Manufacturing: spray-dried dispersion “consisting essentially of 80 mg amorphous enzalutamide and 400 mg HPMCAS”
- Other materials: “one or more inactive excipients” (open-ended)
The therapeutic act is “method of treating prostate cancer” by oral administration of two tablets to deliver a total 160 mg enzalutamide per single dosing event (each tablet contributes 80 mg).
2) Dose and in vivo performance anchors
The claims anchor performance via:
- A systemic exposure equivalence benchmark versus a prior-style reference product with capsules.
- A minimum exposure threshold measured as AUC through day 7.
- Stability endpoints under controlled humidity/temperature and a glass transition temperature criterion.
What do the independent and dependent claims cover?
Claim 1: Exposure equivalence vs a capsule reference
Claim 1 is structured as a comparative bioavailability equivalence claim.
Claim elements:
- Treating prostate cancer by oral dosing male humans in need thereof
- Two tablets, each containing:
- Spray-dried dispersion consisting essentially of 80 mg amorphous enzalutamide + 400 mg HPMCAS
- Inactive excipients
- Performance requirement: for subjects receiving a 160 mg enzalutamide dose, the AUC from the oral two-tablet regimen is equivalent to the AUC from oral dosing four capsules, where each capsule contains:
- 40 mg enzalutamide
- 904.96 mg caprylocaproyl polyoxylglycerides
Practical scope meaning: Claim 1 targets a formulation that matches exposure produced by a specific enzalutamide oral capsule dose-formulation concept (40 mg active with caprylocaproyl polyoxylglycerides excipient loading), but uses an amorphous-spray-dried tablet strategy.
Claim 2: Minimum AUC threshold through 7 days
Claim 2 keeps the identical tablet construction and adds a separate exposure metric.
Performance requirement:
- For subjects receiving a single 160 mg dose, the AUC from dosing to 7 days after dosing must be greater than 150 μg·hr/ml.
Practical scope meaning: Claim 2 covers any tablet embodiments meeting the formulation definition that also achieve durable systemic exposure (extended AUC horizon), independent of the equivalence reference used in Claim 1.
Claim 3: Amorphous-state retention after humidity/temperature storage
Claim 3 adds a solid-state stability condition:
- The amorphous enzalutamide remains amorphous following storage of the spray-dried dispersion at:
- 40°C
- 75% relative humidity
- one month
Practical scope meaning: Claim 3 shifts patent protection toward a stability-maintaining spray-dried dispersion embodiment. It can be infringed by a product whose dispersion composition falls within the “consisting essentially of” limitation and whose amorphous state persists under the stated stress test.
Claim 4: Glass transition temperature constraint after humidity equilibration
Claim 4 uses a thermal property metric:
- Spray-dried dispersion has glass transition temperature > 50°C following:
- equilibration overnight at:
- ambient temperature
- 75% relative humidity
Practical scope meaning: Claim 4 covers formulation embodiments with sufficient Tg for physical stability, again within the “consisting essentially of” dispersion definition.
How broad is the claim coverage?
1) Strong binding terms that limit scope
Across the claims, the following terms narrow the protected formulation space tightly:
- Dose geometry: “two tablets” that each carry 80 mg enzalutamide (total 160 mg)
- Specific dispersion ingredients: spray-dried dispersion “consisting essentially of”:
- 80 mg amorphous enzalutamide
- 400 mg HPMCAS
- Polymer identity: HPMCAS is named explicitly.
- Amorphous requirement: enzalutamide is amorphous in the dispersion; Claim 3 adds post-storage amorphous retention.
These constraints create a narrow structural envelope for tablets and make it less likely a loosely similar formulation would land inside the claim.
2) Open-ended terms that keep some room
- “one or more inactive excipients” is open-ended, allowing:
- tablet binders, disintegrants, lubricants, colorants, etc.
- “consisting essentially of” allows excipients that do not materially change the basic and novel characteristics of the dispersion (depending on claim construction), leaving some flexibility beyond the named drug and polymer.
3) Performance-based language can be both narrowing and “workable”
- Claim 1’s “equivalent AUC” and Claim 2’s “AUC > 150 μg·hr/ml” can narrow scope by requiring empirical performance.
- However, performance thresholds also allow enforceability against products that meet the measurable endpoints even if excipient systems differ (as long as the composition definition is satisfied).
4) Claim type matters: method-of-treatment
Because the claims are method-of-treatment claims, infringement generally hinges on the act of dosing male humans in need of prostate cancer with the claimed product and achieving the claimed exposure/stability conditions. In practice, enforcement can involve:
- sales of a product that, when used as labeled, performs within claimed metrics, and/or
- medical prescribing practices depending on jurisdiction and claim construction.
What is the technical “center of gravity” across the claims?
A single formulation concept
All claims tie back to the same core platform:
- spray-dried dispersion
- 80 mg amorphous enzalutamide
- 400 mg HPMCAS
- delivered as two-tablet, 160 mg dose
The additional claim layers focus on:
- comparative exposure (Claim 1),
- absolute exposure through 7 days (Claim 2),
- amorphous state retention after stress (Claim 3),
- Tg threshold after humidity equilibration (Claim 4).
This is a classic formulation patent strategy: protect the same composition by multiple orthogonal attributes (bioavailability and solid-state stability).
What does the capsule comparison imply about prior art and design-around?
Claim 1’s reference product
The capsule reference uses:
- 40 mg enzalutamide
- 904.96 mg caprylocaproyl polyoxylglycerides
That specific excipient pairing signals that the applicant is benchmarking against an oral capsule approach with a lipid excipient system, likely designed to improve solubility and exposure versus older crystalline or less optimized dosing forms.
Design-around pressure points
To avoid infringement while staying in a similar clinical dose range, a competitor would have to break at least one of:
- the “consisting essentially of” dispersion composition (switch polymer away from HPMCAS or change the drug-polymer ratio materially),
- the spray-dried dispersion approach (use different manufacturing or solid form),
- the two-tablet structure and per-tablet 80 mg amorphous content,
- the measured AUC endpoints (if composition stays within the claim envelope, performance is hard to decouple from dosage form),
- the stability metrics (amorphous persistence and/or Tg).
The most straightforward design-around is to change the polymer system or drug-polymer ratio so that the spray-dried dispersion no longer satisfies “consisting essentially of 80 mg amorphous enzalutamide and 400 mg HPMCAS.” A more conservative strategy is to change manufacturing route such that the product is not “spray-dried dispersion” of the specified amorphous form.
What is the scope of “equivalent AUC” and “AUC > 150” in enforceability terms?
Claim 1: AUC equivalence
“Equivalent AUC” typically invites expert dispute over:
- what equivalence margin applies (regulatory BE standards like 80-125% are often litigated, but claim text does not state a margin),
- whether equivalence is measured as AUClast, AUC0-t, or other interval.
Even without that margin in the claim excerpt provided, the structure indicates:
- equivalence is to the exposure from a defined capsule regimen (four capsules of a defined composition) in a comparable cohort.
Claim 2: hard numeric threshold
Claim 2 is less ambiguous because it specifies:
- AUC from time of dosing to 7 days
- must be > 150 μg·hr/ml
Numeric thresholds typically increase enforceability for formulation performance and reduce interpretive variance.
Solid-state stability claims create a separate infringement pathway
Claim 3: “remains amorphous” after stress
A stability claim turns manufacturing into a litigation focal point:
- product history (batch, storage, packaging)
- test conditions and analysis method used to determine amorphous vs crystalline status
The claim is tied to a specific stress condition:
Claim 4: Tg > 50°C after humidity equilibration
This adds an extra, likely more “material property” style limitation:
- Tg after overnight equilibration at ambient temperature and 75% RH must exceed 50°C.
A competitor with a slightly different spray-dried dispersion microstructure could miss Tg despite matching drug-polymer ratios, depending on how Tg is determined.
How does the patent fit into the broader enzalutamide oral formulation landscape (US)?
1) Market anchor: existing enzalutamide oral dosage forms
In the US, enzalutamide is marketed as oral dosage forms (historically, tablets include specific excipients and crystalline drug form depending on product generation; capsule platforms use lipid excipients). The claim 1 capsule reference explicitly includes caprylocaproyl polyoxylglycerides, indicating the patent positions tablets against a capsule delivery approach with high excipient loading.
2) Patent positioning strategy
The claims indicate a play on two levers that frequently recur in oral small-molecule formulation patents:
- Amorphous solid dispersions for higher apparent solubility and exposure
- Stability reinforcement using polymer selection and microstructure control, measured by Tg and amorphous retention
3) Likely next-generation logic
By locking in:
- a named polymer (HPMCAS),
- specific dispersant ratio,
- stability metrics,
- and defined exposure endpoints,
the patent seeks to protect an “optimized solubility and exposure tablet” even if a competitor uses different excipients outside the dispersion.
What does the scope suggest for competitors running litigation or FTO reviews?
High risk if the product matches the dispersion definition
A product that contains:
- amorphous enzalutamide,
- HPMCAS at the specific 80 mg:400 mg tablet dispersion scale,
- made as a spray-dried dispersion,
- administered as two tablets delivering 160 mg,
will likely trigger at least Claims 2-4 (if performance and stability endpoints are met), and Claim 1 if it matches capsule exposure equivalence.
Moderate risk if only performance matches
If a competitor can match AUC but uses:
- different polymer,
- different drug-polymer ratios,
- or a different dispersion/carrier system,
they may avoid the “consisting essentially of” limitation.
Stability-based workarounds
A competitor may attempt:
- faster crystallization to lower stability metrics (to avoid Claims 3 and 4),
- but such an approach often harms bioavailability, raising Claim 2 risk.
Clinical dose alignment
The dosing geometry (two tablets for 160 mg) is explicit. If a competitor uses a different pill count or different mg-per-tablet, the claim may not read on the product even if systemic exposure matches.
Key takeaways
- US 12,447,128 claims an oral enzalutamide tablet method for prostate cancer built on a spray-dried dispersion of 80 mg amorphous enzalutamide + 400 mg HPMCAS per tablet, dosed as two tablets to deliver 160 mg.
- Claim scope is anchored by measurable exposure outcomes: AUC equivalence to a defined caprylocaproyl polyoxylglycerides capsule regimen (Claim 1) and AUC > 150 μg·hr/ml through 7 days (Claim 2).
- Solid-state stability is protected through stress and thermal properties: amorphous retention after 40°C/75% RH for one month (Claim 3) and Tg > 50°C after overnight equilibration at 75% RH (Claim 4).
- Design-around is constrained because the claims lock key dispersion composition elements via “consisting essentially of” and tie infringement to both performance and stability endpoints.
FAQs
1) Is the patent protecting a new therapeutic regimen or a formulation change?
It is protecting a formulation-and-performance method: the method is “treating prostate cancer” through specific tablet dosing with a defined spray-dried dispersion and measurable AUC and stability endpoints.
2) What must be true about enzalutamide in the claimed tablets?
Enzalutamide must be amorphous in the spray-dried dispersion (and Claim 3 requires it to remain amorphous after a defined storage stress).
3) Does the patent require a specific excipient besides HPMCAS?
It requires the spray-dried dispersion be “consisting essentially of” the named drug and polymer; it allows “one or more inactive excipients” beyond that.
4) Can a competitor meet bioavailability without infringing?
Potentially, if they avoid the “consisting essentially of” dispersion definition and related dose geometry. If they match the dispersion composition and dosing structure, bioavailability thresholds increase infringement risk.
5) Are the stability claims independent of the AUC claims?
Yes. Claims 3 and 4 are stability-property limitations that can be asserted based on storage/thermal measurements even if exposure performance is not the primary issue.
References
[1] United States Patent 12,447,128 (claims as provided).
